Medicare GLP-1 Bridge Program
The Medicare GLP-1 Bridge is a temporary national program providing eligible Medicare beneficiaries with access to certain GLP-1 weight-loss and health-management drugs starting July 1, 2026. This innovative program makes these medications more affordable with a flat $50 monthly copay and operates independently from your regular Medicare Part D coverage.
Program Overview and How to Access It
- Program availability: Available nationwide to all Medicare Part D beneficiaries from July 1, 2026 through December 31, 2027, covering all 50 states and U.S. territories
- Who qualifies: You must be 18 or older with Medicare Part D coverage and meet BMI requirements (35 or higher, or 30+ with certain health conditions like high blood pressure or heart disease, or 27+ with prediabetes or prior cardiovascular events)
- Who doesn't qualify: Those already receiving GLP-1 drugs through their regular Part D plan, people with type 2 diabetes, those with moderate-to-severe sleep apnea, or individuals with fatty liver disease (though these groups may be covered under their Part D plan instead)
- Monthly cost: A simple flat $50 copayment per month for a one-month supply (28 or 30 days), with no deductibles or additional out-of-pocket maximums to meet
- Getting started: Check your eligibility at Medicare.gov, talk with your doctor about whether a GLP-1 drug is right for you, have your provider submit a prescription and prior authorization form, and Medicare will send you a confirmation letter when approved
- Covered medications: Foundayo (tablet), Wegovy (injection or tablet), and Zepbound (KwikPen form only)
- Prior authorization: Valid through December 31, 2027, including for refills and dose changes
- Separate from Part D: The $50 copay does not count toward your Part D deductible or annual out-of-pocket limit, and your regular drug plan coverage remains completely unchanged
Medicare GLP-1 Bridge makes weight-loss medications more accessible to eligible beneficiaries.
Frequently Asked Questions About Medicare GLP-1 Bridge
What is the Medicare GLP-1 Bridge program?
The Medicare GLP-1 Bridge is a temporary demonstration program running from July 1, 2026 through December 31, 2027 that provides eligible Medicare Part D beneficiaries with streamlined access to certain GLP-1 medications. These drugs help with weight management and improving health outcomes. Unlike regular Medicare Part D coverage, the GLP-1 Bridge operates through a separate process managed by Medicare, making it easier for eligible people to obtain these medications at an affordable copay.
Who is eligible for the Medicare GLP-1 Bridge?
To qualify, you must be at least 18 years old and have Medicare Part D drug coverage. Your eligibility depends on your body mass index (BMI) and health conditions. You qualify if you have a BMI of 35 or higher, a BMI between 30 and 34.9 with conditions like uncontrolled high blood pressure, diastolic heart failure, or chronic kidney disease stage 3a or higher, or a BMI between 27 and 29.9 if you have prediabetes, a history of heart attack or stroke, or blocked arteries in your legs or arms. Use the eligibility tool at Medicare.gov/glp1bridge to determine if you qualify.
What is the monthly cost for GLP-1 drugs under the Medicare GLP-1 Bridge?
The copayment is fixed at $50 per month for a one-month supply, whether that's 28 or 30 days depending on the specific medication. This flat rate makes these medications significantly more affordable. Importantly, this $50 payment does not apply to your Medicare Part D deductible or your annual out-of-pocket maximum, keeping it truly separate from your regular drug plan costs. Additionally, copay assistance programs and Low-Income Subsidy benefits cannot reduce this amount.
Which GLP-1 medications are covered under the Medicare GLP-1 Bridge?
Medicare covers three specific GLP-1 medications: Foundayo (available as a tablet), Wegovy (available as either an injection or tablet), and Zepbound (available only as a KwikPen; single-dose vials and other pen formulations are not covered). Your healthcare provider will determine which medication best fits your individual health needs and medical history. The choice depends on factors like your health conditions, preferences for injection versus oral medication, and how your body responds to treatment.
How do I enroll in the Medicare GLP-1 Bridge program?
The enrollment process is straightforward. First, use the eligibility checker at Medicare.gov to verify you qualify. Once confirmed, schedule an appointment with your doctor or healthcare provider to discuss whether a GLP-1 medication is appropriate for you. Your healthcare provider will send a prescription to your pharmacy and submit the required prior authorization form. Medicare will then review your information, and you'll receive a confirmation letter in the mail when your coverage is approved. After that, you can fill your prescription at any participating pharmacy and pay the $50 copay.
Will the Medicare GLP-1 Bridge affect my existing Part D coverage?
No, the Medicare GLP-1 Bridge is completely separate from your regular Medicare Part D drug plan. Medications furnished through the GLP-1 Bridge do not count toward your Part D deductible, do not apply to your out-of-pocket maximum, and do not affect your regular Part D costs or coverage. Your Part D plan coverage for all other medications continues exactly as before. Additionally, Medicare Part D plan sponsors do not have to opt in to the GLP-1 Bridge because it operates outside the standard Part D benefit structure.
Understanding the requirements and details helps you determine if the GLP-1 Bridge is right for you.
Important Program Requirements
Provider Certification: Your healthcare provider must certify that you will use the GLP-1 medication as part of a comprehensive lifestyle program that includes diet and exercise modifications. This ensures the medication is part of a complete weight management strategy.
Prescription and Prior Authorization: Your doctor or healthcare provider must send the prescription to a pharmacy and submit a prior authorization form when requested. Once approved, the prior authorization remains valid through December 31, 2027, including for refills and dose adjustments unless you switch to a different GLP-1 medication.
Who Should Not Apply
The Medicare GLP-1 Bridge is not designed for everyone. You are not eligible if you:
- Already receive GLP-1 drugs covered through your regular Medicare Part D plan
- Have a type 2 diabetes diagnosis (your Part D plan should cover GLP-1s for diabetes management)
- Have been diagnosed with moderate-to-severe sleep apnea
- Have fatty liver disease (though your Part D plan may cover GLP-1s for this condition)
If you fall into one of these categories, speak with your healthcare provider or contact Medicare directly at 1-800-633-4227 to discuss your coverage options under your regular Part D plan.
Ready to Learn More?
Check your eligibility and find out if the Medicare GLP-1 Bridge program is right for you.
Visit Medicare.gov or call 1-800-MEDICARE (1-800-633-4227) to get started today.
TTY users can call 1-877-486-2048
Contact Maryland Medicare Options for more information on Maryland's GPL-1 coverage options at (410) 896-1212.
Next Steps
If you believe you're eligible for the Medicare GLP-1 Bridge program, take these action steps:
- Check your eligibility: Use the eligibility tool at Medicare.gov to confirm you meet the requirements
- Contact your doctor: Schedule an appointment to discuss whether a GLP-1 medication is appropriate for your health situation
- Get a prescription: Work with your provider to submit the prescription and prior authorization
- Wait for confirmation: Medicare will mail you a letter confirming your coverage under the GLP-1 Bridge
- Fill your prescription: Visit your pharmacy with the confirmation and pay the $50 monthly copay
Sources: Information compiled from Medicare.gov (Weight loss drugs coverage page) and the Centers for Medicare & Medicaid Services (CMS.gov) Medicare GLP-1 Bridge program page. Program details are current as of July 2026 and apply to the GLP-1 Bridge demonstration period ending December 31, 2027. For the most up-to-date information and eligibility verification, visit Medicare.gov/coverage/weight-loss-drugs or call 1-800-MEDICARE.
